GlaxoSmithKline plc Total Assets 2011-2026 | GSK

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets GlaxoSmithKline plc

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
59.5 B	59 B	60.1 B	79.1 B	80.4 B	79.7 B	58.1 B	56.4 B	59.1 B	53.4 B	40.7 B	42.1 B	41.5 B	41.1 B

All numbers in GBP currency

Indicator range from annual reports

Maximum	Minimum	Average
80.4 B	40.7 B	57.9 B

Quarterly Total Assets GlaxoSmithKline plc

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	79.1 B	-	-	-	80.4 B	-	-	-	79.7 B	-	-	-	58.1 B	-	-	-	56.4 B	-	-	-	59.1 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in GBP currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
80.4 B	56.4 B	68.8 B

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	1.36 B	$ 3.44	-4.32 %	$ 1.03 B	Canada
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
ADMA Biologics ADMA	624 M	$ 15.36	-2.17 %	$ 3.66 B	USA
Cellectis S.A. CLLS	384 M	$ 3.53	-3.54 %	$ 116 M	France
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Apellis Pharmaceuticals APLS	1.08 B	$ 20.28	0.65 %	$ 2.56 B	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Nymox Pharmaceutical Corporation NYMX	654 K	-	-19.68 %	$ 18.4 M	Canada
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Aptorum Group Limited APM	16.1 M	$ 0.79	-1.15 %	$ 4.31 M	China
Autolus Therapeutics plc AUTL	783 M	$ 1.51	1.35 %	$ 385 M	Britain
China SXT Pharmaceuticals SXTC	21.7 M	$ 2.01	-1.36 %	$ 2.86 M	China
Galmed Pharmaceuticals Ltd. GLMD	18.5 M	$ 0.67	7.08 %	$ 624 K	Israel
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Anika Therapeutics ANIK	271 M	$ 14.05	-1.44 %	$ 206 M	USA
ANI Pharmaceuticals ANIP	1.28 B	$ 74.36	-1.64 %	$ 1.44 B	USA
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
AVEO Pharmaceuticals AVEO	105 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	690 M	$ 162.43	0.6 %	$ 8.08 B	USA
BioCryst Pharmaceuticals BCRX	490 M	$ 8.49	-0.18 %	$ 1.75 B	USA
BridgeBio Pharma BBIO	936 M	$ 65.66	-0.78 %	$ 12.6 B	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Brainstorm Cell Therapeutics BCLI	1.83 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Bellerophon Therapeutics BLPH	7.94 M	-	-74.18 %	$ 955 K	USA
Bellicum Pharmaceuticals BLCM	23.8 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	226 M	-	-7.31 %	$ 87 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
BioLineRx Ltd. BLRX	38.9 M	$ 2.69	-0.74 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	7.59 B	$ 61.3	1.21 %	$ 11.8 B	USA
Burford Capital Limited BUR	3.11 B	$ 7.79	-5.75 %	$ 1.28 B	Britain
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA